Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Jan-Feb;47(1):100-102.
doi: 10.1590/S1677-5538.IBJU.2019.0713.1.

Editorial Comment: Endoclips as novel fiducial markers in trimodality bladder preserving therapy of muscle-invasive bladder carcinoma: feasibility and patient out-comes

Rodolfo Borges Dos Reis  1 , Valdair Francisco Muglia  2 , Antônio Antunes Rodrigues Júnior  1 , Gustavo Viani  2
Affiliations
Editorial

Editorial Comment: Endoclips as novel fiducial markers in trimodality bladder preserving therapy of muscle-invasive bladder carcinoma: feasibility and patient out-comes

Rodolfo Borges Dos Reis et al. Int Braz J Urol. 2021 Jan-Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

None declared.

Comment on

References

    1. Pos F, Remeijer P. Adaptive management of bladder cancer radiotherapy. Semin Radiat Oncol. 2010;20:116–120. - PubMed
    2. 1. Pos F, Remeijer P. Adaptive management of bladder cancer radiotherapy. Semin Radiat Oncol. 2010;20:116-20. - PubMed
    1. de Ridder M, Gerbrandy LC, de Reijke TM, Hinnen KA, Hulshof MCCM. BioXmark® liquid fiducial markers for image-guided radiotherapy in muscle invasive bladder cancer: a safety and performance trial. Br J Radiol. 2020;93:20200241–20200241. - PMC - PubMed
    2. 2. de Ridder M, Gerbrandy LC, de Reijke TM, Hinnen KA, Hulshof MCCM. BioXmark® liquid fiducial markers for image-guided radiotherapy in muscle invasive bladder cancer: a safety and performance trial. Br J Radiol. 2020;93:20200241. - PMC - PubMed
    1. Wortel K, Hovius MC, van Andel G, de Reijke TM, Hulshof MCCM. The Feasibility and Utility of Cystoscopy-Guided Hydrogel Marker Placement in Patients With Muscle-Invasive Bladder Cancer. Pract Radiat Oncol. 2020;10:195–201. - PubMed
    2. 3. Wortel K, Hovius MC, van Andel G, de Reijke TM, Hulshof MCCM. The Feasibility and Utility of Cystoscopy-Guided Hydrogel Marker Placement in Patients With Muscle-Invasive Bladder Cancer. Pract Radiat Oncol. 2020;10:195-201. - PubMed
    1. Freilich JM, Spiess PE, Biagioli MC, Fernandez DC, Shi EJ, Hunt DC, et al. Lipiodol as a fiducial marker for image-guided radiation therapy for bladder cancer. Int Braz J Urol. 2014;40:190–197. - PubMed
    2. 4. Freilich JM, Spiess PE, Biagioli MC, Fernandez DC, Shi EJ, Hunt DC, et al. Lipiodol as a fiducial marker for image-guided radiation therapy for bladder cancer. Int Braz J Urol. 2014;40:190-7. - PubMed
    1. Garcia MM, Gottschalk AR, Brajtbord J, Konety BR, Meng MV, Roach M, 3rd, et al. Endoscopic gold fiducial marker placement into the bladder wall to optimize radiotherapy targeting for bladder-preserving management of muscle-invasive bladder cancer: feasibility and initial outcomes. PLoS One. 2014;9:e89754. Erratum in: PLoS One. 2016;11:e0164558. - PMC - PubMed
    2. 5. Garcia MM, Gottschalk AR, Brajtbord J, Konety BR, Meng MV, Roach M 3rd, et al. Endoscopic gold fiducial marker placement into the bladder wall to optimize radiotherapy targeting for bladder-preserving management of muscle-invasive bladder cancer: feasibility and initial outcomes. PLoS One. 2014;9:e89754. Erratum in: PLoS One. 2016;11:e0164558. - PMC - PubMed